Radioimmunotherapy combo may aid in colorectal cancer treatment

08/11/2013 |

A study in the Journal of Nuclear Medicine found radioimmunotherapy with a combination of Cu-64 labeled DOTA-cetuximab and cisplatin may halt colorectal tumor growth. Researchers evaluated therapeutic response in mice with KRAS-mutated HCT116 tumors. "Together, these data suggest that Cu-64 specifically delivered to epidermal growth factor receptor-positive tumors by cetuximab can suppress tumor growth despite the KRAS status and present opportunities for personalized clinical treatment strategies in colorectal cancer," the authors wrote.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health